Previous
Next
We’re committed to ensuring you receive your prescription at the lowest available price.

Eligible patients may pay as little as $25*

With our Savings Card, eligible commercially-insured patients with coverage pay as little as $25* for each prescription!*

*Copay offer subject to eligibility. See Terms and Conditions below.

How to save on your Quillivant XR® (methylphenidate HCI) prescription

Tirs ADHD Copay Card with Dollar Sign Icon Find a Pharmacy Visit PharmacyLocator.TrisPharma.com or call 866-315-2636

Tirs ADHD Copay Card with Dollar Sign Icon Show your Card Show your card, either on your phone or a print-out, to the pharmacist

Tirs ADHD Copay Card with Dollar Sign Icon Questions? If you have questions about savings, please call 888-840-7006

Terms and Conditions

With the Tris Co-pay Savings Card, eligible commercially-insured and cash-paying patients can lower their out-of-pocket costs for their prescription. Eligible patients may pay as little as $25 on each prescription. Program benefit calculated on FDA-approved dosing. A valid Prescriber ID# is required on the prescription. Patients with questions about the Tris Savings offer should call 1-888-840-7006. ALL offers are for a 30 Day Supply of medication.

Restrictions: This offer is valid in the United States and Puerto Rico. Offer not valid for prescriptions reimbursed under Medicaid, a Medicare drug benefit plan, TRICARE, or other federal or state health programs (such as medical assistance programs). Cash Discount Cards and other non-insurance plans are not valid as primary under this offer. If the patient is eligible for drug benefits under any such program, the patient cannot use this offer. By using this offer, the patient certifies that he or she will comply with any terms of his or her health insurance contract requiring notification to his or her payer of the existence and/or value of this offer. It is illegal to (or offer to) sell, purchase, or trade this offer. This offer is not transferable and is limited to one offer per person. Not valid if reproduced. Void where prohibited by law. Tris Pharma reserves the right to rescind, revoke, or amend this offer without notice at any time.

Important Safety Information

Quillivant® XR (methylphenidate HCI) is a federally controlled substance (CII) because it contains methylphenidate that can be a target for people who abuse prescription medicines or street drugs. Quillivant XR has a high chance for abuse and misuse and may lead to substance use problems, including addiction. Keep Quillivant XR in a safe place to prevent abuse and misuse. Never give your Quillivant XR to anyone else, because it may cause death or harm them. Selling or giving away Quillivant XR may harm others and is against the law.

See Additional Important Safety Information.
To report SUSPECTED ADVERSE REACTIONS, contact Tris Pharma, Inc. at (732) 940-0358 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Important Safety Information

Quillivant® XR (methylphenidate HCI) is a federally controlled substance (CII) because it contains methylphenidate that can be a target for people who abuse prescription medicines or street drugs. Quillivant XR has a high chance for abuse and misuse and may lead to substance use problems, including addiction. Keep Quillivant XR in a safe place to prevent abuse and misuse. Never give your Quillivant XR to anyone else, because it may cause death or harm them. Selling or giving away Quillivant XR may harm others and is against the law.

Your healthcare provider should check you or your child’s risk for abuse, misuse, and addiction before starting treatment with Quillivant XR and will monitor you or your child during treatment. Tell your physician if you, your child, or any family members have ever abused or been dependent on alcohol, prescription medicines, or street drugs.

Quillivant XR should not be taken if you or your child are allergic to methylphenidate hydrochloride, or any of the ingredients in Quillivant XR, or are taking or have taken within the past 14 days an antidepression medicine called a monoamine oxidase inhibitor or MAOI.

The following have been reported with the use of methylphenidate hydrochloride and other stimulant medicines:

  • Risks for people with serious heart disease: Sudden death has happened in people who have heart defects or other serious heart disease. Before starting Quillivant XR, tell your healthcare provider if you or your child have any heart problems, heart disease, or heart defects.
    Call your healthcare provider or go to the nearest hospital emergency room right away if you or your child has any signs of heart problems such as chest pain, shortness of breath, or fainting during treatment with Quillivant XR.
  • Increase in blood pressure and heart rate.
    Your healthcare provider should check your or your child’s blood pressure and heart rate regularly during treatment with Quillivant XR.
  • Mental (psychiatric) problems, including new or worse behavior and thought problems, new or worse bipolar illness, new psychotic symptoms (such as hearing voices, or seeing or believing things that are not real) or new manic symptoms. Tell your healthcare provider about any mental problems you or your child have, or about a family history of suicide, bipolar illness, or depression. Call the doctor right away if there are any new or worsening mental symptoms during treatment.

Quillivant XR may not be right for you or your child. Before starting Quillivant XR tell your or your child’s health care provider about all health conditions (or a family history of) including:

  • heart problems, heart disease, heart defects, or high blood pressure
  • mental problems including psychosis, mania, bipolar illness, or depression
  • circulation problems in fingers and toes
  • have eye problems, including increased pressure in your eye, glaucoma, or problems with your close-up vision (farsightedness)
  • have or had repeated movements or sounds (tics) or Tourette’s syndrome, or have a family history of tics or Tourette’s syndrome
  • if you are pregnant or plan to become pregnant. It is not known if Quillivant XR will harm the unborn baby. There is a pregnancy registry for females who are exposed to Quillivant XR during pregnancy. The purpose of the registry is to collect information about the health of females exposed to Quillivant XR and their baby. If you or your child becomes pregnant during treatment with Quillivant XR, talk to your healthcare provider about registering with the National Pregnancy Registry for Psychostimulants at 1-866-961-2388 or https://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/othermedications/.
  • if you are breastfeeding or plan to breast feed. Quillivant XR passes into your breast milk. You and your healthcare provider should decide if you will take Quillivant XR or breastfeed.
  • Do not start any new medicine while taking Quillivant XR without talking to your healthcare provider first.

What should I avoid while taking Quillivant XR?

Quillivant XR should not be taken with MAOI medicines or if you stopped taking an MAOI in the last 14 days. Do not drink alcohol while taking Quillivant XR. This may cause a faster release of your methylphenidate dose.

Quillivant XR may cause serious side eff­ects, including:

  • See “What is the most important information I should know about Quillivant XR?” for information on reported heart and mental problems

Other serious side eff­ects include:

  • Circulation problems in fingers and toes (peripheral vasculopathy, including Raynaud’s phenomenon). Tell your healthcare provider if you or your child have numbness, pain, skin color change, or sensitivity to temperature in your fingers or toes.
    Call the doctor right away if you or your child have any signs of unexplained wounds appearing on fingers or toes during treatment with Quillivant XR.
  • New or worsening tics or worsening Tourette’s syndrome. Tell your healthcare provider if you or your child get any new or worsening tics or worsening Tourette’s syndrome during treatment with Quillivant XR.
  • Painful and prolonged erections (priapism) have occurred with methylphenidate. If you or your child develop priapism seek medical help right away. Because priapism can cause long lasting damage, it should be checked by a health care provider right away.
  • Slowing of growth (height and weight) in children. Children should have their height and weight checked often during treatment with Quillivant XR. Quillivant XR treatment may be stopped if your child is not gaining weight or height.
  • Eye problems (increased pressure in the eye and glaucoma). Call your healthcare provider right away if you or your child develop changes in your vision or eye pain, swelling, or redness.

Most Common side eff­ects include:

  • Decreased appetite
  • Trouble sleeping
  • Nausea
  • Vomiting
  • Indigestion
  • Stomach pain
  • Weight loss
  • Anxiety
  • Dizziness
  • Irritability
  • Mood swings
  • Fast heart beat
  • Increased blood pressure

These are not all the possible side effects of Quillivant XR.

To report SUSPECTED ADVERSE REACTIONS, contact Tris Pharma, Inc. at (732) 940-0358 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

What is Quillivant XR?

Quillivant XR is a central nervous system stimulant prescription medicines. Quillivant XR is a chewable tablet.

Quillivant XR is used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Quillivant XR may help increase attention and decrease impulsiveness and hyperactivity in people with ADHD.

It is not known if Quillivant XR is safe and effective in children under 6 years of age.

Please see Full Prescribing Information for Quillivant XR, including Boxed Warning about Abuse, Misuse and Addiction, and Medication Guide.

How can we help?

Sign up to get answers or request more information on Quillivant XR® (methylphenidate HCI)

up arrowTop